125 related articles for article (PubMed ID: 17088231)
21. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats.
Thornton E; Vink R; Blumbergs PC; Van Den Heuvel C
Brain Res; 2006 Jun; 1094(1):38-46. PubMed ID: 16697978
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of self-reported movement dysfunction among young adults with a history of ecstasy and methamphetamine use.
Todd G; Burns L; Pearson-Dennett V; Esterman A; Faulkner PL; Wilcox RA; Thewlis D; Vogel AP; White JM
Drug Alcohol Depend; 2019 Dec; 205():107595. PubMed ID: 31600615
[TBL] [Abstract][Full Text] [Related]
23. Degradation of βII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions.
Kobeissy FH; Liu MC; Yang Z; Zhang Z; Zheng W; Glushakova O; Mondello S; Anagli J; Hayes RL; Wang KK
Mol Neurobiol; 2015 Aug; 52(1):696-709. PubMed ID: 25270371
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats.
Pike BR; Flint J; Dave JR; Lu XC; Wang KK; Tortella FC; Hayes RL
J Cereb Blood Flow Metab; 2004 Jan; 24(1):98-106. PubMed ID: 14688621
[TBL] [Abstract][Full Text] [Related]
25. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
26. Temporal and spatial profile of Bid cleavage after experimental traumatic brain injury.
Franz G; Beer R; Intemann D; Krajewski S; Reed JC; Engelhardt K; Pike BR; Hayes RL; Wang KK; Schmutzhard E; Kampfl A
J Cereb Blood Flow Metab; 2002 Aug; 22(8):951-8. PubMed ID: 12172380
[TBL] [Abstract][Full Text] [Related]
27. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
Gouzoulis-Mayfrank E; Daumann J
J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
[TBL] [Abstract][Full Text] [Related]
28. Can the severity of dependence scale be usefully applied to 'ecstasy'?
Bruno R; Matthews AJ; Topp L; Degenhardt L; Gomez R; Dunn M
Neuropsychobiology; 2009; 60(3-4):137-47. PubMed ID: 19893331
[TBL] [Abstract][Full Text] [Related]
29. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
30. Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice.
Thompson SN; Gibson TR; Thompson BM; Deng Y; Hall ED
Exp Neurol; 2006 Sep; 201(1):253-65. PubMed ID: 16814284
[TBL] [Abstract][Full Text] [Related]
31. Methamphetamine and MDMA (ecstasy) neurotoxicity: 'of mice and men'.
Itzhak Y; Achat-Mendes C
IUBMB Life; 2004 May; 56(5):249-55. PubMed ID: 15370888
[TBL] [Abstract][Full Text] [Related]
32. MDMA ("ecstasy") and neurotoxicity.
Mithoefer M; Jerome L; Doblin R
Science; 2003 Jun; 300(5625):1504-5; author reply 1504-5. PubMed ID: 12791964
[No Abstract] [Full Text] [Related]
33. Ecstasy: pharmacology and neurotoxicity.
Morton J
Curr Opin Pharmacol; 2005 Feb; 5(1):79-86. PubMed ID: 15661630
[TBL] [Abstract][Full Text] [Related]
34. Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats.
Kobeissy FH; Jeung JA; Warren MW; Geier JE; Gold MS
Addict Biol; 2008 Mar; 13(1):15-25. PubMed ID: 17910739
[TBL] [Abstract][Full Text] [Related]
35. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.
Reneman L; de Win MM; van den Brink W; Booij J; den Heeten GJ
J Psychopharmacol; 2006 Mar; 20(2):164-75. PubMed ID: 16510475
[TBL] [Abstract][Full Text] [Related]
36. Enzymatic-nonenzymatic cellular antioxidant defense systems response and immunohistochemical detection of MDMA, VMAT2, HSP70, and apoptosis as biomarkers for MDMA (Ecstasy) neurotoxicity.
Riezzo I; Cerretani D; Fiore C; Bello S; Centini F; D'Errico S; Fiaschi AI; Giorgi G; Neri M; Pomara C; Turillazzi E; Fineschi V
J Neurosci Res; 2010 Mar; 88(4):905-16. PubMed ID: 19798748
[TBL] [Abstract][Full Text] [Related]
37. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats.
Clemens KJ; Cornish JL; Li KM; Hunt GE; McGregor IS
Neuropharmacology; 2005 Aug; 49(2):195-207. PubMed ID: 15993443
[TBL] [Abstract][Full Text] [Related]
38. Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia.
Capela JP; Meisel A; Abreu AR; Branco PS; Ferreira LM; Lobo AM; Remião F; Bastos ML; Carvalho F
J Pharmacol Exp Ther; 2006 Jan; 316(1):53-61. PubMed ID: 16183702
[TBL] [Abstract][Full Text] [Related]
39. Apoptotic and antiapoptotic mechanisms after traumatic brain injury.
Keane RW; Kraydieh S; Lotocki G; Alonso OF; Aldana P; Dietrich WD
J Cereb Blood Flow Metab; 2001 Oct; 21(10):1189-98. PubMed ID: 11598496
[TBL] [Abstract][Full Text] [Related]
40. Neurotoxicity mechanisms of thioether ecstasy metabolites.
Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
